Skip to main content
. 2020 Nov 30;10:20819. doi: 10.1038/s41598-020-77269-7

Table 2.

The relationship between TLG and clinicopathological characteristics in patients with lung cancer.

Characteristics Low TLG (n = 47) High TLG (n = 72) p-value
Sex
Male 29 (61.7) 28 (38.9) 0.015
Female 18 (38.3) 44 (61.1)
Age
< 65 5 (10.60 12 (16.7) 0.578
65–74 21 (44.7) 33 (45.8)
> 75 21 (44.7) 27 (37.5)
TNM
I 27 (57.4) 15 (20.8) < 0.001
II 8 (17.0) 14 (19.4)
III 12 (25.5) 43 (59.7)
ECOG-PS
0/1 28 (59.6) 40 (55.6) 0.665
≥ 2 19 (40.4) 32 (44.4)
Inflammatory response
mGPS
 0 31 (66.0) 27 (37.5) 0.006
 1 7 (14.9) 13 (18.1)
 2 9 (19.1) 32 (44.4)
NLR
< 3 26 (55.3) 27 (37.5) 0.146
3–5 12 (25.5) 23 (31.9)
> 5 9 (19.1) 22 (30.6)
MUST
Low risk 29 (61.7) 22 (30.6) 0.003
Intermediate risk 15 (31.9) 37 (51.4)
High risk 3 (6.4) 13 (18.1)
Body composition
BMI kg/m2
< 25 19 (40.4) 37 (51.4) 0.241
 ≥ 25 28 (59.6) 35 (48.6)
Visceral obesity
VFA 128.94 (15.33–577.08) 140.19 (14.35–549.90) 0.683
Visceral obesity
No 17 (36.2) 28 (38.9) 0.765
Yes 30 (63.8) 44 (61.1)
SMI 43.34 (29.43–66.36) 45.35 (29.40–74.36) 0.350
Low SMI
No 24 (51.1) 37 (51.4) 0.972
Yes 23 (48.9) 35 (48.6)
SMD 31.80 (9.58–48.04) 35.31 (13.98–51.24) 0.098
Low SMD
No 15 (31.9) 30 (41.7) 0.284
Yes 32 (68.1) 42 (58.3)
Survival
Survival rate (3 year)
 No 26 (55.3) 58 (80.6) 0.003
 Yes 21 (44.7) 14 (19.4)

TNM Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group Performance Status, mGPS modified Glasgow Prognostic Score, NLR Neutrophil Lymphocyte Ratio, MUST Malnutrition Universal Screening Tool, BMI Body Mass Index, VFA Visceral Fat Area, SMI Skeletal Muscle Index, SMD Skeletal Muscle Density, TLG Total Lesion Glycolysis.